FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033854540> ?p ?o ?g. }

• W3033854540 endingPage "1514" @default.
• W3033854540 startingPage "1514.2" @default.
• W3033854540 abstract "Background: Little is known about mortality in patients with systemic lupus erythematosus (SLE) presenting with neuropsychiatric (NP) symptoms. Objectives: We aimed to evaluate all-cause and cause-specific mortality in patients with SLE and NP symptoms. Methods: All patients with the clinical diagnosis of SLE of 18 years and older that visited the tertiary referral NPSLE clinic of the Leiden University Medical Center between 2007-2018 and signed informed consent were included in this study. Patients were classified as NPSLE if NP symptoms were attributed to SLE and immunosuppressive or anticoagulant therapy was initiated, otherwise patients were classified as non-NPSLE. Municipal registries were checked for current status (alive/deceased). Electronical medical files were studied for clinical characteristics and cause of death. Standardized mortality ratios (SMRs) and 95% confidence intervals were calculated using data from the general Dutch population. In addition, a rate ratio (RR) was calculated using direct standardization to compare mortality in NPSLE with non-NPSLE patients. Results: 351 patients with the clinical diagnosis of SLE were included, of which 149 patients were classified as NPSLE (42.5%). Compared with the general population, mortality was increased five times in NPSLE (SMR 5.0, 95% CI: 2.6-8.5) and nearly four times in non-NPSLE patients (SMR 3.7, 95% CI: 2.2-6.0), as shown in Table 1. Risk of death due to cardiovascular disease (CVD) was increased in non-NPSLE patients (SMR 6.2, 95% CI: 2.0-14.6) and an increased risk of death to infections was present in both NPSLE and non-NPSLE patients ((SMR 29.9, 95% CI: 3.5 – 105) and SMR 91.3 (95% CI: 18.8 – 266) respectively). However, mortality did not differ between NPSLE and non-NPSLE patients (RR 1.0, 95% CI: 0.5 – 2.0). Table 1. All-cause mortality in SLE patients presenting with neuropsychiatric symptoms attributed to SLE (NPSLE) or to other causes (non-NPSLE) NPSLE (N = 149) Non-NPSLE (N = 202) Deaths (N, % ) 13 (8.7) 17 (8.4) Age at death (median, range ) 49 (32 – 79) 59 (20 – 89) Follow-up time (years ) 906 1047 Crude mortality rate (per 1000 PY ) 14.3 16.2 All-cause mortality* Female 5.5 (2.8 – 9.6) 3.4 (1.9 – 5.7) Male 2.3 (0.1 - 12.8) 6.2 (1.3 – 18.2) Combined 5.0 (2.6 – 8.5) 3.7 (2.2 – 6.0) * Standardized mortality ratio, ratio of the observed and expected number of deaths Conclusion: Mortality was increased in both NPSLE and non-NPSLE patients in comparison with the general population, but there was no difference in mortality between NPSLE and non-NPSLE patients. Risk of death due to infections was increased in both groups. Disclosure of Interests: Rory Monahan: None declared, Rolf Fronczek: None declared, Jeroen Eikenboom: None declared, Huub Middelkoop: None declared, L.J.J. Beaart- van de Voorde: None declared, Gisela Terwindt: None declared, Nic van der Wee: None declared, Frits Rosendaal: None declared, Thomas Huizinga Grant/research support from: Ablynx, Bristol-Myers Squibb, Roche, Sanofi, Consultant of: Ablynx, Bristol-Myers Squibb, Roche, Sanofi, Margreet Kloppenburg: None declared, G.M. Steup-Beekman: None declared" @default.
• W3033854540 created "2020-06-12" @default.
• W3033854540 creator A5007458836 @default.
• W3033854540 creator A5031487360 @default.
• W3033854540 creator A5037097906 @default.
• W3033854540 creator A5041823391 @default.
• W3033854540 creator A5043817969 @default.
• W3033854540 creator A5045361419 @default.
• W3033854540 creator A5051357297 @default.
• W3033854540 creator A5052842332 @default.
• W3033854540 creator A5054269152 @default.
• W3033854540 creator A5054925850 @default.
• W3033854540 creator A5078150048 @default.
• W3033854540 date "2020-06-01" @default.
• W3033854540 modified "2023-10-16" @default.
• W3033854540 title "AB0430 MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS" @default.
• W3033854540 doi "https://doi.org/10.1136/annrheumdis-2020-eular.939" @default.
• W3033854540 hasPublicationYear "2020" @default.
• W3033854540 type Work @default.
• W3033854540 sameAs 3033854540 @default.
• W3033854540 citedByCount "0" @default.
• W3033854540 crossrefType "journal-article" @default.
• W3033854540 hasAuthorship W3033854540A5007458836 @default.
• W3033854540 hasAuthorship W3033854540A5031487360 @default.
• W3033854540 hasAuthorship W3033854540A5037097906 @default.
• W3033854540 hasAuthorship W3033854540A5041823391 @default.
• W3033854540 hasAuthorship W3033854540A5043817969 @default.
• W3033854540 hasAuthorship W3033854540A5045361419 @default.
• W3033854540 hasAuthorship W3033854540A5051357297 @default.
• W3033854540 hasAuthorship W3033854540A5052842332 @default.
• W3033854540 hasAuthorship W3033854540A5054269152 @default.
• W3033854540 hasAuthorship W3033854540A5054925850 @default.
• W3033854540 hasAuthorship W3033854540A5078150048 @default.
• W3033854540 hasBestOaLocation W30338545401 @default.
• W3033854540 hasConcept C102803821 @default.
• W3033854540 hasConcept C107130276 @default.
• W3033854540 hasConcept C126322002 @default.
• W3033854540 hasConcept C179755657 @default.
• W3033854540 hasConcept C187212893 @default.
• W3033854540 hasConcept C2779134260 @default.
• W3033854540 hasConcept C2908647359 @default.
• W3033854540 hasConcept C29374701 @default.
• W3033854540 hasConcept C44249647 @default.
• W3033854540 hasConcept C71924100 @default.
• W3033854540 hasConcept C99454951 @default.
• W3033854540 hasConceptScore W3033854540C102803821 @default.
• W3033854540 hasConceptScore W3033854540C107130276 @default.
• W3033854540 hasConceptScore W3033854540C126322002 @default.
• W3033854540 hasConceptScore W3033854540C179755657 @default.
• W3033854540 hasConceptScore W3033854540C187212893 @default.
• W3033854540 hasConceptScore W3033854540C2779134260 @default.
• W3033854540 hasConceptScore W3033854540C2908647359 @default.
• W3033854540 hasConceptScore W3033854540C29374701 @default.
• W3033854540 hasConceptScore W3033854540C44249647 @default.
• W3033854540 hasConceptScore W3033854540C71924100 @default.
• W3033854540 hasConceptScore W3033854540C99454951 @default.
• W3033854540 hasIssue "Suppl 1" @default.
• W3033854540 hasLocation W30338545401 @default.
• W3033854540 hasOpenAccess W3033854540 @default.
• W3033854540 hasPrimaryLocation W30338545401 @default.
• W3033854540 hasRelatedWork W2074737604 @default.
• W3033854540 hasRelatedWork W2084510133 @default.
• W3033854540 hasRelatedWork W2115436619 @default.
• W3033854540 hasRelatedWork W2329379289 @default.
• W3033854540 hasRelatedWork W2336382044 @default.
• W3033854540 hasRelatedWork W2391995530 @default.
• W3033854540 hasRelatedWork W2403614928 @default.
• W3033854540 hasRelatedWork W2473332645 @default.
• W3033854540 hasRelatedWork W2808466081 @default.
• W3033854540 hasRelatedWork W3026228164 @default.
• W3033854540 hasVolume "79" @default.
• W3033854540 isParatext "false" @default.
• W3033854540 isRetracted "false" @default.
• W3033854540 magId "3033854540" @default.
• W3033854540 workType "article" @default.